Contract Research Organization Services (CROs) - Global Strategic Business Report: Capitalize on a $149.1B Market by 2030 as IQVIA, ICON, Parexel and WuXi AppTec Accelerate AI-Led Trials

WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model

How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated

Peptide Manufacturing Trends: How Oral Dosing Raises API Demand

Frost & Sullivan awards WuXi AppTec with 2026 Global Company of the Year Recognition for CRDMO Leadership

WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year

Global Drug Development Services Market Report 2026 | Capitalize on AI and Precision Medicine as IQVIA, Labcorp, Lonza, ICON, and WuXi AppTec Compete for a $50.26B Market by 2030

WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability

Top China Biopharma Stocks to Watch, According to Bernstein

Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River

Is WuXi AppTec's Buyback Campaign Working Amid Mounting US Pressure?

603259 Stock Price and Chart — SSE:603259